Slide 1: Q2 2024 Results Conference Call and Webcast
Q2 2024 Results Conference Call and Webcast August 1, 2024 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchan
Slide 3: Q2 Earnings Results Call Agenda
Q2 Earnings Results Call Agenda Bijal Desai, MBA Paul Moore, Ph.D. Ken Galbraith VP, Finance & Strategy CSO Chair and CEO • Financial Update • R&D Update • Q&A • Q&A • Q&A Making a Meaningful Difference 3
Slide 4: Bijal Desai, MBA
Bijal Desai, MBA VP, Finance & Strategy Making a Meaningful Difference 4
Slide 5: 2H 2024 Key Completed Milestones
2H 2024 Key Completed Milestones • FDA granted our partner Jazz Priority Review of the biologics license application (BLA) for zanidatamab as second-line (2L) treatment for HER2+ biliary tract cancers (BTC) in the United States with target action date of November 29, 2024 • The European Medicines Ag
Slide 6: Q2 2024 YTD Financial Results
Q2 2024YTD Financial Results • Revenue decreased in Q2 2024YTD primarily due to lower In millions USD Q2 2024YTD Q2 2023YTD development support payments from Jazz and lower revenue from our partners for research support and other payments compared to Q2 2023YTD, partially offset by milestone revenue
Slide 7: Projected Cash Runway Supports R&D Priorities into 2H 2027
Projected Cash Runway Supports R&D Priorities into 2H 2027 Current Financial Status: Potential sources to extend cash runway beyond 2H 2027: • Cash resources1 of approx. $395.9M (as of June 30, 2024) • Additional regulatory approval and commercial milestones for zanidatamab from Jazz and • Cash reso
Slide 8: Paul Moore, Ph.D.
Paul Moore, Ph.D. Chief Scientific Officer Making a Meaningful Difference 8
Slide 9: Diversified Portfolio of Wholly-Owned Candidates
Diversified Portfolio of Wholly-Owned Candidates Designing next-generation antibody-drug conjugates (ADC) and T cell engagers (TCE) on targets with evidence of clinical activity and addressing areas of unmet therapeutic potential Research and Target Late- Early-Development IND-Enabling Phase 1 Phase
Slide 10: Targeting FRα Provides Strategic Diversification: Balancing ADC and TCE Portfolios
Targeting FRα Provides Strategic Diversification: Balancing ADC and TCE Portfolios Across Therapeutic Area of Focus mRNA Expression Profile of Select Cancer Target in Ovarian Cancer (N=421) A balanced portfolio of ADCs targeting clinically validated FRa and NaPi2b, along with a T cell engager target
Slide 11: Moderate to Strong Expression of MSLN is Frequent in Ovarian Cancer, Pancreatic Cancer, NSCLC
Moderate to Strong Expression of MSLN is Frequent in Ovarian Cancer, Pancreatic Cancer, NSCLC, and Endometrial Cancer 100 IHC 5.1 Proportion of Patients with MSLN+ Tumors (%) 90 8.4 3+ Strong 80 83.8 2+ Mod 70 12 11.1 1+ Weak 60 21.9 4.4 0 30% 70% 100% TPS 50 19 53 21.3 40 14.1 40.6 29 13.8 30 MSLN
Slide 12: Designed with a 2+1 Antibody Format to Enhance Safety and Anti-Tumor Activity
Designed with a 2+ 1 Antibody Format to Enhance Safety and Anti-Tumor Activity ZW171 What is the 2+1 Antibody Format in ZW171 ? • 2 anti-MSLN paratopes to enable avid tumor selective binding • 1 anti-CD3 paratope to ensure MSLN dependent redirected T cell activation and tumor cell killing Benefits o
Slide 13: ZW171 Mediates Cytotoxicity Against High and Moderate MSLN-Expressing Tumor Cells
ZW171 Mediates Cytotoxicity Against High and Moderate MSLN-Expressing Tumor Cells ZW171 exhibits MSLN-dependent cytotoxicity in MSLN-expressing lung, ovarian, colon, and mesothelioma cancer cell lines H292 High MSLN Expressing (Lung cancer) Moderate MSLN Expressing Low MSLN Expressing (Normal-like)
Slide 14: Global Phase 1 Study in MSLN-Expressing Solid Tumors (NCT06523803)
Global Phase 1 Study in MSLN-Expressing Solid Tumors (NCT06523803) Open-label, FIH, dose-escalation study KEY ELIGIBILITY CRITERIA Part 1: Dose Escalation N= ~160 Part 2: Dose Expansion Inclusion criteria • Pathologically confirmed cancers with Ovarian Cancer Cohort evidence of locally advanced (unr
Slide 15: FRα is Frequently Overexpressed in NSCLC, Ovarian Cancer, and Endometrial Cancer
FRα is Frequently Overexpressed in Non-Small Cell Lung Cancer, Ovarian Cancer, and Endometrial Cancer 100 TPS 10-25%, IHC>2+ Ovarian Cancer, PS2+ Scoring Proportion of Patients with FR⍺+ Tumors (%) 90 TPS 25-50%, IHC>2+ • ~35% of PROC tumors score as FR⍺-High (TPS≥75%, TPS >50%, IHC>2+ 80 IHC≥2+) 70
Slide 16: ZD06519 Designed in Alignment with Understanding of ADC Mechanisms
ZD06519 was Designed in Alignment with our Understanding of ADC Mechanisms Featuring Moderate Potency and “Sweet Spot” Linker Stability • A combination of moderate potency and “sweet spot” stability is expected to enable a high protein dose • Hypothesis supported by limited doses reached by exatecan
Slide 17: ZW191 Demonstrates Effective 3D Tumor Model Penetration
ZW191 Demonstrates Effective 3D Tumor Model Penetration Tumor Spheroid Penetration Tumor Spheroid Penetration High FRα Expression, JEG3 Cell Line, 50 nM High FRα Expression, JEG3 Cell Line, 50 nM, 24hours 1,200 Outer Inner 4 hours 4 hours 96 hours layers layers 1,000 Mean FLuorescence Intensity ZW1
Slide 18: Zymeworks: A Differentiated Product Pipeline Built on Unique Capabilities
Zymeworks: A Differentiated Product Pipeline Built on Unique Capabilities in Antibody Engineering and Medicinal Chemistry Seeking to address unmet patient 5 new INDs planned Pipeline Events needs in HER2+ GI Cancers Focus on Gyn CA, Lung CA, & GI CA • Jazz initiated a Phase 3 trial to zanidatamab •
Slide 19: Q&A
Q&A Ken Galbraith Chair & CEO Paul Moore, Ph.D. CSO Bijal Desai, MBA VP, Finance & Strategy Making a Meaningful Difference 19